Pharmaceutical intermediates
Baricitinib Intermediates
3 pharmaceutical intermediates for Baricitinib. Indication: Juvenile Rheumatoid Arthritis; Alopecia Areata; COVID-19 Infection; Atopic Dermatitis; Rheumatoid Arthritis.
About Baricitinib
- Originator
- Incyte Corp
- Indication
- Juvenile Rheumatoid Arthritis; Alopecia Areata; COVID-19 Infection; Atopic Dermatitis; Rheumatoid Arthritis
- Approved Date
- 10/08/2019
- DS/DP
- 03/10/2029
Available intermediates
3 intermediates currently listed for Baricitinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile | 1187595-85-2 | / | / |
| 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | 1029716-44-6 | / | / |
| 4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine | 941685-27-4 | / | / |
Building toward Baricitinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →